Relation Deepens GSK AI Pact With Up to $110M Deal Aiming at Transformationally Different Success Rates in Drug Discovery

Relation Therapeutics has expanded its AI-driven research collaboration with GSK in a deal valued at up to $110 million, building on an earlier partnership focused on fibrotic diseases and osteoarthritis. The new agreement centers on generating large-scale human cellular perturbation datasets—showing how human cells respond to genetic and drug interventions—to train Relation’s MORGAN foundation model and other AI tools. This shift moves the relationship beyond target discovery in specific diseases toward developing the underlying AI infrastructure and data engine that can be applied across multiple disease areas, including immunology and inflammation. Both companies explicitly tie the initiative to improving drug-discovery success rates and accelerating timelines, with GSK framing the goal as yielding medicines that are more likely to succeed, faster. The collaboration also reflects GSK’s broader strategy of integrating AI into early-stage R&D and Relation’s ambition to scale its automated, biology-first discovery platform.